Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Redox Rep ; 22(6): 563-571, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28657497

RESUMO

OBJECTIVES: This study investigated the potential anti-inflammatory effect of hesperidin against carrageenan induced pleurisy in rat model. METHODS: Twenty-four adult female Wistar rats (350 - 450g) were grouped as follows: Group I: rats were administered saline solution only (Normal control group); Group II: rats were administered saline solution (NaCl 0.9%) orally and injected with carrageenan (Inflammation control group); Group III: rats were administered hesperidin only (Hesperidin group); Group IV: rats were administered hesperidin orally and intrapleurally injected with 2% carrageenan (Inflammation treated with hesperidin group). The exudate volume, total leukocyte count, reactive oxygen species (ROS), myeloperoxidase (MPO),δ-aminolevulinate dehydratase (δ-ALA-D), catalase (CAT), superoxide dismutase (SOD), activities as well as non-protein thiol group (NPSH) and thiobarbituric acid reactive substances (TBARS) levels were determined. RESULTS: Pretreatment with hesperidin at a dose of 80 mg/kg orally per day for 21 days, minimized the increase in pleural exudate volume and leucocyte count and modulated the activities of MPO, SOD and CAT, as well as the levels of ROS, NPSH and TBARS in carrageenan-induced rats. CONCLUSION: Our results suggest that hesperidin can elicit its anti-inflammatory action by blocking exudate and leukocyte influx into pleural cavity, inhibiting MPO activity and preventing oxidative damage.


Assuntos
Anti-Inflamatórios/uso terapêutico , Hesperidina/uso terapêutico , Pleurisia/tratamento farmacológico , Pleurisia/metabolismo , Animais , Catalase/metabolismo , Glutationa/metabolismo , Inflamação/tratamento farmacológico , Inflamação/metabolismo , Fígado/efeitos dos fármacos , Fígado/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Peroxidase/metabolismo , Sintase do Porfobilinogênio/metabolismo , Ratos , Ratos Wistar , Espécies Reativas de Oxigênio/metabolismo , Superóxido Dismutase/metabolismo , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo
2.
Microb Pathog ; 104: 32-38, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28062289

RESUMO

Chagas disease (CD) is caused by Trypanosoma cruzi, an intracellular protozoan which is a potent stimulator of cell-mediated immunity. In the indeterminate form of CD (IFCD) a modulation between pro- and anti-inflammatory responses establishes a host-parasite adaptation. It was previously demonstrated that purinergic ecto-enzymes regulates extracellular ATP and adenosine levels, influencing immune and inflammatory processes during IFCD. In inflammatory sites ATP, as well as its degradation product, adenosine, function as signaling molecules and immunoregulators through the activation of purinergic receptors. In this work, it was analyzed the gene and protein expression of P2X7 purinergic receptor in peripheral lymphocytes and serum immunoregulatory cytokines from IFCD patients. Gene and protein expression of P2X7 receptor (P2X7R), and serum cytokines (IL-2, IL-10, IL-17 and IFN-γ) were unaltered. However, IFCD group showed significantly higher IL-4 and IL-6 levels while TNF-α was significantly decreased. These results indicate that imune profile of IFCD patients displays anti-inflammatory characteristics, consistent with the establishment of an immunomodulatory response. Further study about the molecular knowledge of P2X7R in IFCD is useful to clarify the participation of purinergic system in the regulatory mechanism which avoid the progression of CD.


Assuntos
Doença de Chagas/genética , Doença de Chagas/imunologia , Expressão Gênica , Imunidade Celular , Linfócitos/imunologia , Linfócitos/metabolismo , Receptores Purinérgicos P2X7/genética , Estudos de Casos e Controles , Doença de Chagas/diagnóstico , Doença de Chagas/parasitologia , Citocinas/metabolismo , Humanos , Imunomodulação , Mediadores da Inflamação/metabolismo , Masculino , Pessoa de Meia-Idade , Receptores Purinérgicos P2X7/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA